Background: To improve productivity of automated platelet
(PLT) collection, the industry has introduced new instruments
or modifications to existing equipment. Materials
and Methods: Data obtained from 8 regular PLT apheresis
donors randomized to double- (DDC) or triple-dose PLT collection
(TDC) with the BAXTER Amicus (AM), the HAEMONETICS
MCS Plus (MCS+), and the GAMBRO Trima Accel (TA)
were evaluated focusing on duration, citrate infusion and
product quality, and statistically compared to data obtained
from the same donors during DDC on our current equipment
(GAMBRO Trima V4 (TV4) and Spectra LRS-Turbo V7
(SPC)). Results: All units were sufficiently leukoreduced to
below 1 × 106 white blood cells (WBCs). Apart from statistically
significant lower pH values and higher CD62P expression
observed with AM units, no differences in in vitro function
were noted during storage. Compared to our current
equipment, the new devices had advantages for whole
blood processed, and, except for MCS+, for needle time, collection
volume, collection rate, and collection efficiency. PLT
yield and processing time were equivalent, except for TA
which was the fastest machine. MCS+ was the slowest device
owing to statistically significant lower draw and collection
rates which were, however, compensated by fewer citrate
reactions due to only moderate citrate infusion rates.
Conclusion: Despite equal or better efficiencies, collection
procedures with the new devices did not automatically increase
the number of units per day, particularly if quick donation
was counteracted by long overall performance (AM).
TA was the fastest and hence offered the highest potential
to optimize productivity. MCS+ showed better donor comfort,
as reflected by lower draw and citrate infusion rates,
but was also the slowest.